Literature DB >> 21755536

Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years.

Christopher G Goetz1, Glenn T Stebbins, Bichun Ouyang.   

Abstract

The objective of the study was to assess the development and evolution of visual and nonvisual hallucinations in patients with Parkinson's disease over 10 years. Hallucinations increase over time, but minimal attention has been placed on nonvisual domains. We studied 60 patients with Parkinson's disease who had never hallucinated at baseline and followed them over 10 years. The Rush Hallucination Inventory monitored frequency and type (visual, auditory, tactile, olfactory) of hallucinations at baseline and after 0.5, 1.5, 4, 6, and 10 years. Descriptive statistics were applied, and general estimating equation modeling assessed longitudinal risks. Over 10 years, visual hallucinations were endorsed by patients more frequently than other sensory modalities. Whereas isolated visual hallucinations dominated the early hallucination profile, visual plus nonvisual hallucinations accounted for progressively higher proportions of hallucinators over 10 years: 0.5 years, 0%; 4 years, 26%; 6 years, 47%; 10 years, 60% (odds ratio, 1.17; confidence interval, 1.01-1.37; P = .04). Once visual plus nonvisual hallucinations developed, the risk of continuing to have multidomain hallucinations was high (odds ratio, 3.67; confidence interval, 1.13-11.93; P = .03). Hallucination severity was highly associated with current visual plus nonvisual hallucinations (odds ratio, 4.06; confidence interval, 2.93-5.61; P < .0001) and the continuation of multidomain hallucinations (odds ratio, 1.58; confidence interval, 1.12-2.24; P = .01). Whereas visual hallucinations in isolation are classic in Parkinson's disease, nonvisual hallucinations emerge over time, and the combination of visual with nonvisual hallucinations predominates in late Parkinson's disease. To capture the breadth and severity of hallucinations in chronically hallucinating patients with Parkinson's disease, screening inventories and practice-based interviews must include questions on both visual and nonvisual components.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21755536     DOI: 10.1002/mds.23835

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  21 in total

1.  "String Hallucinations": Multimodal Tactile and Visual Hallucinations in Parkinson's Disease.

Authors:  Jesús Pérez-Pérez; Javier Pagonabarraga; Ramón Fernández-Bobadilla; Jaime Kulisevsky
Journal:  Mov Disord Clin Pract       Date:  2015-11-23

Review 2.  Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.

Authors:  Daniel Martinez-Ramirez; Michael S Okun; Michael S Jaffee
Journal:  Neurodegener Dis Manag       Date:  2016-07-13

3.  Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.

Authors:  Jennifer G Goldman; Glenn T Stebbins; Vy Dinh; Bryan Bernard; Doug Merkitch; Leyla deToledo-Morrell; Christopher G Goetz
Journal:  Brain       Date:  2014-01-29       Impact factor: 13.501

Review 4.  Lewy Body Degenerations as Neuropsychiatric Disorders.

Authors:  Jared T Hinkle; Gregory M Pontone
Journal:  Psychiatr Clin North Am       Date:  2020-04-08

Review 5.  Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction.

Authors:  Marco Onofrj; Alberto J Espay; Laura Bonanni; Stefano Delli Pizzi; Stefano L Sensi
Journal:  Mov Disord       Date:  2019-07-15       Impact factor: 10.338

Review 6.  The characteristic features of auditory verbal hallucinations in clinical and nonclinical groups: state-of-the-art overview and future directions.

Authors:  Frank Larøi; Iris E Sommer; Jan Dirk Blom; Charles Fernyhough; Dominic H Ffytche; Kenneth Hugdahl; Louise C Johns; Simon McCarthy-Jones; Antonio Preti; Andrea Raballo; Christina W Slotema; Massoud Stephane; Flavie Waters
Journal:  Schizophr Bull       Date:  2012-04-12       Impact factor: 9.306

Review 7.  Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.

Authors:  Eva Schaeffer; Daniela Berg
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

8.  Treatment of psychosis and dementia in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden
Journal:  Curr Treat Options Neurol       Date:  2014-03       Impact factor: 3.598

9.  Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration.

Authors:  Xuehan Ren; Jeffrey Lin; Sheng Luo; Christopher G Goetz; Glenn T Stebbins; Esther Cubo
Journal:  Parkinsonism Relat Disord       Date:  2019-08-31       Impact factor: 4.891

Review 10.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.